Nasolacrimal Duct Obstruction Treatments
Nasolacrimal duct obstruction occurs when the narrow channel that drains tears from the eye into the nasal cavity becomes blocked, causing persistent tearing, infection risk, and significant discomfort. The primary surgical remedy is dacryocystorhinostomy, a procedure that creates a new drainage opening between the lacrimal sac and the nasal cavity, and researchers are actively comparing the traditional external approach — which requires a small skin incision — against endoscopic techniques performed entirely through the nose and leaving no external scar. Central questions in the field concern whether adjuncts like mitomycin C, an anti-scarring agent applied during surgery, meaningfully improve long-term patency rates, and how best to manage more complex cases involving canalicular stenosis or obstruction present from birth.
- Works
- 19,147
- Total citations
- 128,504
- Keywords
- DacryocystorhinostomyEndoscopicExternalNasolacrimal Duct ObstructionCongenital Nasolacrimal Duct ObstructionLacrimal Drainage System
Top papers in Nasolacrimal Duct Obstruction Treatments
Ordered by total citation count.
- An Electron Microscopic Study↗ 1,138
- The International Workshop on Meibomian Gland Dysfunction: Executive Summary↗ 1,012OA
- Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy↗ 1,001OA
- The International Workshop on Meibomian Gland Dysfunction: Report of the Definition and Classification Subcommittee↗ 884OA
- Perifollicular Xanthomatosis as the Hallmark of Axillary Fox-Fordyce Disease↗ 727
- IgG4‐Related Disease: Clinical and Laboratory Features in One Hundred Twenty‐Five Patients↗ 660OA
- Macular hole surgery with and without internal limiting membrane peeling↗ 652
- US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey↗ 638
- Prevalence of Ocular Surface Disease in Glaucoma Patients↗ 630
- Tear physiology and dry eyes↗ 561
- The diagnostic utility of serum IgG4 concentrations in IgG4-related disease↗ 544OA
- Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4‐related systemic disease↗ 525
Active researchers
Top authors in this area, ranked by h-index.